Macrocyclic inhibitors of HCV NS3 protease

Bibliography

• World health organization Fact sheet number 164, October 2000
   Google Scholar
• Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 2000;20:1-16
   PubMed Web of Science ®Google Scholar
• Brown RS Jr, Gaglio PJ. Scope of worldwide hepatitis C problem. Liver Transpl 2003;9:S10-3
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-92
   PubMed Web of Science ®Google Scholar
• Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alpha-2b alone or in combination with ribavirin for treatment of relapse of chronic hepatitis C. N Engl J Med 1998;339:1493-9
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alpha-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-172
   PubMed Web of Science ®Google Scholar
• Heathcote EJ, Shiffman ML, Cooksley WGE, et al. Peginterferon alpha-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000;343:1673-80
   PubMed Web of Science ®Google Scholar
• Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65
   PubMed Web of Science ®Google Scholar
• Lamarre D, Anderson PC, Bailey M, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003:186-9
   Google Scholar
• Yip Y, Victor F, Lamar J, et al. Discovery of a novel bicycloproline P2 bearing peptidyl [alpha]-ketoamide LY514962 as HCV protease inhibitor. Bioorg Med Chem Lett 2004;14:251-6
   Google Scholar
• Dymock BW. Emerging therapies for Hepatitis C infection. Emerg Drugs 2001;6:13-42
   PubMedGoogle Scholar
• De Francesco R, Migliaccio G. Challenges and successes in developing new therapies for hepatitis C. Nature 2005;436:953-60
   PubMed Web of Science ®Google Scholar
• Perni RB, Farmer LJ, Cottrell KM, et al. Inhibitors of hepatitis C virus NS3.4A protease. Part 3: P2 proline variants. Bioorg Med Chem Lett 2004;14:1939-42
   Google Scholar
• Roboisson P, dekock H, Rosenquist A, et al. Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350. Bioorg Med Chem Lett 2008;18:4853-8
   Google Scholar
• Liverton NJ, Holloway MK, McCauley JA, et al. Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A protease. J Am Chem Soc 2008;130:4607-9
   Google Scholar
• Brazil M. Antiviral drugs: macrocyclic inhibitor for hepatitis C. Nat Rev Drug Discov 2003;212:945
   Google Scholar
• Tsantrizos YS, Bolger G, Bonneau P, et al. Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection. Angew Chem Int Ed 2003;42:1356
   PubMed Web of Science ®Google Scholar
• Kaito M, Watnabe S, Tsukiyama-Kohara K, et al. Hepatitis C virus particle detected by immunoelectron microscopic study. J Gen Virol 1994;75:1755-60
   PubMed Web of Science ®Google Scholar
• Bartenschlager R. The NS3/4A proteinase of the hepatitis C virus: unravelling structure and function of an unusual enzyme and a prime target for antiviral therapy. J Viral Hep 1999;6:165-81
   Google Scholar
• Bartenschlager R, Ahlborn-Laake L, Mous J, Jacobsen H. Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions. J Virol 1993;67:3835-44
   PubMed Web of Science ®Google Scholar
• Reed KE, Rice CM. Molecular characterization of hepatitis C virus. In: Reesink HW, editor, Hepatitis C Virus, Basel, Switzerland: Karger. 1998. p. 1-37
   Google Scholar
• Lindenbach BD, Rice CM. Unravelling hepatitis C virus replication from genome to function. Nature 2005;436:933-8
   PubMed Web of Science ®Google Scholar
• Yan Y, Li Y, Munshi S, et al. Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: a 2.2 A resolution structure in a hexagonal crystal form. Protein Sci 1998;7:837-47
   PubMed Web of Science ®Google Scholar
• Love RA, Parge HE, Wickersham JA, et al. The crystal structure of Hepatitis C Virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell 1996;87:331-42
   PubMed Web of Science ®Google Scholar
• Kim JL, Morgenstern KA, Griffith JP, et al. Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: the crystal structure provides insights into the mode of unwinding. Structure 1998;6:89-100
   PubMed Web of Science ®Google Scholar
• Kwong AD, Kim JL, Rao G, et al. Hepatitis C virus NS3/4A protease. Antiviral Res 1998;40:1-18
   PubMed Web of Science ®Google Scholar
• Kim JL, Morgenstern KA, Lin C, et al. Thomson. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 1996;87:343
   PubMed Web of Science ®Google Scholar
• Steinkuhler C, Urbani A, Tomei L, et al. Activity of purified hepatitis C virus protease NS3 on peptide substrates. J Virol 1996;70:6694-700
   Google Scholar
• Urbani A, Bianchi E, Narjes F, et al. Substrate specificity of the Hepatitis C virus serine protease NS3. J Biol Chem 1997;272:9204-9
   PubMed Web of Science ®Google Scholar
• Kolykhalov AA, Agapov EV, Rice CM. Specificity of the hepatitis C virus NS3 serine protease: effects of substitutions at the 3/4A, 4A/4B, 4B/5A, and 5A/5B cleavage sites on polyprotein processing. J Virol 1994;68:7525-33
   Google Scholar
• Perni RB, Almquist SJ, Byrn RA, et al. Preclinical profile of VX-950, a potent, selective, and orally, bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicob Agents Chemother 2006;50:899-909
   PubMed Web of Science ®Google Scholar
• Tyndall JDA, Fairlie DP. Macrocycles mimic the extended peptide conformation recognized by aspartic, serine, cysteine, and metallo Proteases. Curr Med Chem 2001;8:893-907
   Google Scholar
• Venkatraman S, Njoroge FG, Girijavallabhan VM, et al. Design and synthesis of depeptidized macrocyclic inhibitors of hepatitis C NS3-4A protease using structure-based drug design. J Med Chem 2005;48:5088-91
   Google Scholar
• Schering Plough. Macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising alkyl and aryl alanine P2 moieties. US6914122; Issued 2005
   Google Scholar
• Chen KX, Njoroge FG, Prongay A, et al. Synthesis and biological activity of macrocyclic inhibitors of hepatitis C virus (HCV) NS3 protease. Bioorg Med Chem Lett 2005;15:4475-8
   Google Scholar
• Marchetti A, Ontoria JM, Matassa VG. Synthesis of two novel cyclic biphenyl ether analogs of an inhibitor of HCV NS3 protease. Synlett 1999;S1:1000-2
   Google Scholar
• Chen KX, Njoroge FG, Arasappan A, et al. Novel potent hepatitis C virus NS3 serine protease inhibitors derived from proline-based macrocycle. J Med Chem 2006;49:995-1005
   PubMed Web of Science ®Google Scholar
• Schering Plough. Macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising N-cyclic P2 moieties. US6846802; Issued 2005
   Google Scholar
• Arasappan A, Chen KX, Njoroge FG, et al. Novel dipeptide macrocycles from 4-Oxo, -Thio, and -Amino-substituted proline derivatives. J Org Chem 2002;67:3923-6
   Google Scholar
• Chen KX, Njoroge FG, Vibulbhan B, et al. Syntheses of novel 4-tert-Alkyl Ether proline-based 16- and 17-membered macrocyclic compounds. J Org Chem 2002;67:2730-3
   Google Scholar
• Chen KX, Njoroge FG, Vibulbhan B, et al. Proline-based macrocyclic inhibitors of the hepatitis C virus: stereoselective synthesis and biological activity. Angew Chem Int Ed Engl 2005;44:7024-8
   PubMed Web of Science ®Google Scholar
• Chen KX, Njoroge FG, Pichardo J, et al. Potent 7-Hydroxy-1, 2,3,4-tetrahydroisoquinoline-3-carboxylic acid-based macrocyclic inhibitors of hepatitis C virus NS3 protease. J Med Chem 2006;49:546-74
   Google Scholar
• Goudreau N, Brochu C, Cameron DR, et al. Potent inhibitors of the hepatitis C virus NS3 protease: design and synthesis of macrocyclic substrate-based β-strand mimics. J Org Chem 2004;69:6185-201
   PubMed Web of Science ®Google Scholar
• Merck. Macrocyclic compounds as HCV NS3 protease. WO2006119061
   Google Scholar
• Merck. HCV NS3 protease inhibitors. US2007027071
   Google Scholar
• IRBM. Macrocyclic compounds as antiviral agents. WO2007148135
   Google Scholar
• Merck and IRBM. HCV NS3 protease inhibitors. WO2008051475
   Google Scholar
• Merck and IRBM. HCV NS3 protease inhibitors. WO2008051477
   Google Scholar
• Merck. HCV NS3 protease inhibitors. WO2008051514
   Google Scholar
• Merck. HCV NS3 protease inhibitors. WO2008057209
   Google Scholar
• Merck. Macrocyclic peptides as HCV NS3 protease inhibitors. WO2007016441
   Google Scholar
• Boehringer Ingelheim. Macrocyclic peptides active agaist the hepatitis C virus. US2000059929
   Google Scholar
• Boehringer Ingelheim. Macrocyclic peptides active agaist the hepatitis C virus. WO2004037855
   Google Scholar
• Intermune. Macrocyclic compounds as inhibitors of viral replication. US2005267018
   Google Scholar
• Intermune and Array. Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication. WO2005037214
   Google Scholar
• Boehringer Ingelheim. Macrocyclic peptides active against the hepatitis C virus. WO2005070955
   Google Scholar
• Pfizer. Inhibitors of hepatitis C virus protease, and composition and treatments using the same. WO2006043145
   Google Scholar
• Enanta. Quinoxalinyl macrocyclic hepatitis C virus serine protease inhibitors. US2007299078
   Google Scholar
• Enanta. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors. WO2004093798
   Google Scholar
• Enanta. Tetrazolyl macrocyclic peptides as hepatitis C serine protease inhibitors. WO2008019289
   Google Scholar
• Enanta. Macrocyclic oximyl hepatitis C protease inhibitors. US2007281884
   Google Scholar
• Bristol-Myers Squibb. Inhibitors of hepatitis C virus. US20080107625
   Google Scholar
• Bristol-Myers Squibb. Inhibitors of hepatitis C virus. US20080107624
   Google Scholar
• Bristol-Myers Squibb. Inhibitors of hepatitis C virus. WO2008057871
   Google Scholar
• Bristol-Myers Squibb. Inhibitors of hepatitis C virus US20080107623
   Google Scholar
• Enanta. Triazolyl macrocyclic peptides as hepatitis C serine protease inhibitors. WO2008021960
   Google Scholar
• Enanta. Macrocyclic hepatitis C virus HCV) serine protease inhibitors. WO2004072243
   Google Scholar
• Enanta. Pyridazinonyl macrocyclic peptides as hepatitis C serine protease inhibitors. WO2008019303
   Google Scholar
• Chiron. Aryl-containing macrocyclic compounds. WO2007001406
   Google Scholar
• Bristol Myers Squibb. Macrocyclic isoquinoline peptide inhibitors of hepatitis C virus. WO2004094452
   Google Scholar
• Bristol Myers Squibb. Inhibitors of hepatitis C virus. WO2003053349
   Google Scholar
• Intermune. Macrocyclic compounds as inhibitors of viral replication. WO2005095403
   Google Scholar
• Boehringer Ingelheim. Macrocyclic peptides active against the hepatitis C virus. WO2005028501
   Google Scholar
• Schering Plough. Depeptidized inhibitors of hepatitis C virus NS3 protease. WO2005051980
   Google Scholar
• Gilead. Antiviral compounds. WO2006020276
   Google Scholar
• Bristol-Myers Squibb. Hepatitis C virus inhibitors. WO2007044933
   Google Scholar
• Enanta. Macrocyclic oximyl hepatitis C protease inhibitors. WO2007143694
   Google Scholar
• Enanta. Acylaminoheteroaryl hepatitis C protease inhibitors. WO2008021956
   Google Scholar
• Enanta. Arylalkoxyl hepatitis C protease inhibitors. WO2008022006
   Google Scholar
• Bristol-Myers Squibb. Inhibitors of hepatitis C virus. WO2008057873
   Google Scholar
• Intermune and Array. Novel macrocyclic inhibitors of hepatitis C virus replication. WO2007015824
   Google Scholar
• Tibotec and Medivir. Macrocyclic inhibitors of hepatitis C virus. WO2007014920
   Google Scholar
• Tibotec and Medivir. Macrocyclic inhibitors of hepatitis C virus. WO2007014918
   Google Scholar
• Tibotec and Medivir. Macrocyclic inhibitors of hepatitis C virus. WO2007014921
   Google Scholar
• Medivir. Macrocyclic inhibitors of hepatitis C virus. WO2007017144
   Google Scholar
• Medivir. Macrocyclic inhibitors of hepatitis C virus. WO2007014925
   Google Scholar
• Medivir. HCV NS-3 serine protease inhibitors. WO2005073216
   Google Scholar
• Tibotec and Medivir. Macrocyclic inhibitors of hepatitis C virus. WO2007014926
   Google Scholar
• Tibotec and Medivir. Macrocyclic inhbitors of hepatitis C virus. WO2007014927
   Google Scholar
• Tibotec and Medivir. Macrocyclic inhibitors of hepatitis C virus. WO2007014923
   Google Scholar
• Medivir. HCV NS-3 serine protease inhibitors. WO2005073195
   Google Scholar
• Tibotec. Macrocyclic inhibitors of hepatitis C virus. WO2007014919
   Google Scholar
• Tibotec and Medivir. Macrocylic inhibitors of hepatits C virus. WO2007014922
   Google Scholar
• Tibotec. Macrocyclic inhibitors of hepatitis C virus. WO2007014924
   Google Scholar
• Tibotec and Medivir. HCV inhibiting macrocyclic phenylcarbamates. WO2008096001
   Google Scholar
• Tibotec and Medivir. Pyrimidine substituted macrocyclic HCV inhibitors. WO2008095999
   Google Scholar
• Gilead. Antiviral compounds. WO2007009109
   Google Scholar
• Novartis. Macrocyclic compounds as HCV NS3 protease inhibitors. WO2008101665
   Google Scholar
• Novartis. Organic compounds and their uses. WO2008033389
   Google Scholar
• Merck. HCV NS3 protease inhibitors. WO2008057208
   Google Scholar
• Seiwert SD, Andrews SW, Jiang Y, et al. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227). Animicrob Agents Chemother 2008;52:4432-41
   PubMed Web of Science ®Google Scholar
• Lin T-I, Lenz O, Fanning G, et al. In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor. Antimicrob Agents Chemother 2009;53:1377-85
   PubMed Web of Science ®Google Scholar